Escient Pharmaceuticals, Inc.

Receptos, Inc.

Celgene International II Sarl

Janssen Pharmaceutica Nv

Ortho-mcneil Pharmaceutical Corp.

Pfizer Corporation

Vertex Pharmaceuticals, Inc.

Liming Huang

Esther Martinborough

Marcus F Boehm

Adam Richard Yeager

Junko Tamiya

Manisha Moorjani

Enugurthi Brahmachary

Thomas Fowler

Premji Meghani

Andrew Richard Novak

Marcos Sainz

Brandon Selfridge

Michael Knaggs

Marion Lanier

J Guy Breitenbucher

Kelly J McClure

Robert Peach

Michael Allen Hanson

Jennifer L Brooks

Fiona Lorraine Scott

Gregg Alan Timony

Laurent Gomez

Michael D Hack

Frank Urban Axe

Nigel P Shankley

Kristen L Arienti

Clark A Sehon

Alice Lee

Mark T Griffith

Daniel Glynn

Magda F Morton

Terrance D Barrett

Mark Mills

Mark Thomas Miller

Peter D J Grootenhuis

Matthew Michael Hamilton

Lewis R Makings

Anna Hazlewood

Song Liu

Simon Paul Planken

Sarah S Hadida Ruah

Elizabeth Ann Lunney

Philip Turnbull

Greg P Iacobini

Matthew Richard Crittall

Brahmachary Enugurthi

Ashavini K Singh

Kelly J Mcclure

Frank U Axe

Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 dependent condition more specifically, by contacting the MRGPR X2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Modulators of mas-related g-protein receptor X2 and related products and methods

Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 or a MRGPR X2 ortholog dependent condition, more specifically, by contacting the MRGPR X2 or the MRGPR X2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein A, B, C, D, E, G, W, Y, Z, R, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Modulators of mas-related G-protein receptor X2 and related products and methods

Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition, more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Modulators of Mas-related G-protein receptor X2 and related products and methods

Methods are provided for modulating MRGPRX2 or a MRGPRX2 ortholog generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Methods are provided for modulating MRGPRX2 generally, or for treating a MRGPRX2 dependent condition more specifically, by contacting the MRGPRX2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein D, W, Z, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q, Q, Z, R, R, R, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

Modulators of Mas-related G-protein receptor X4 and related products and methods

Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein m, n, p, t, A, B, Z, R, Rand Rare as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

Modulators of mas-related g-protein receptor X4 and related products and methods

Modulators of mas-related G-protein receptor X4 and related products and methods

Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as products containing such compounds, and methods of their use and synthesis. Such compounds have the structure of Formula (I) below: (I) or pharmaceutically acceptable salts thereof, wherein A, J, W, Y, Z, R, R, Rand Rare as defined herein. 

GLP-1 receptor modulators

Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where '' represents either or both the R and S form of the compound): where A, B, C, Y, Y, Z, R, R, R, R, R, W, n, p and q are as defined herein.

Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated.

Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis

Growing community of inventors

San Diego, CA, United States of America

Liming Huang